Opposing roles of the entero-pancreatic hormone urocortin-3 in glucose metabolism in rats.
Blood glucose
Corticotropin-releasing factor receptor 2
Gastric emptying
Glucose absorption
Insulin secretion
Somatostatin
Urocortin-3
Journal
Diabetologia
ISSN: 1432-0428
Titre abrégé: Diabetologia
Pays: Germany
ID NLM: 0006777
Informations de publication
Date de publication:
06 2022
06 2022
Historique:
received:
04
08
2021
accepted:
20
12
2021
pubmed:
25
3
2022
medline:
11
5
2022
entrez:
24
3
2022
Statut:
ppublish
Résumé
Urocortin-3 (UCN3) is a glucoregulatory peptide produced in the gut and pancreatic islets. The aim of this study was to clarify the acute effects of UCN3 on glucose regulation following an oral glucose challenge and to investigate the mechanisms involved. We studied the effect of UCN3 on blood glucose, gastric emptying, glucose absorption and secretion of gut and pancreatic hormones in male rats. To supplement these physiological studies, we mapped the expression of UCN3 and the UCN3-sensitive receptor, type 2 corticotropin-releasing factor receptor (CRHR2), by means of fluorescence in situ hybridisation and by gene expression analysis. In rats, s.c. administration of UCN3 strongly inhibited gastric emptying and glucose absorption after oral administration of glucose. Direct inhibition of gastrointestinal motility may be responsible because UCN3's cognate receptor, CRHR2, was detected in gastric submucosal plexus and in interstitial cells of Cajal. Despite inhibited glucose absorption, post-challenge blood glucose levels matched those of rats given vehicle in the low-dose UCN3 group, because UCN3 concomitantly inhibited insulin secretion. Higher UCN3 doses did not further inhibit gastric emptying, but the insulin inhibition progressed resulting in elevated post-challenge glucose and lipolysis. Incretin hormones and somatostatin (SST) secretion from isolated perfused rat small intestine was unaffected by UCN3 infusion; however, UCN3 infusion stimulated secretion of somatostatin from delta cells in the isolated perfused rat pancreas which, unlike alpha cells and beta cells, expressed Crhr2. Conversely, acute antagonism of CRHR2 signalling increased insulin secretion by reducing SST signalling. Consistent with these observations, acute drug-induced inhibition of CRHR2 signalling improved glucose tolerance in rats to a similar degree as administration of glucagon-like peptide-1. UCN3 also powerfully inhibited glucagon secretion from isolated perfused rat pancreas (perfused with 3.5 mmol/l glucose) in a SST-dependent manner, suggesting that UCN3 may be involved in glucose-induced inhibition of glucagon secretion. Our combined data indicate that UCN3 is an important glucoregulatory hormone that acts through regulation of gastrointestinal and pancreatic functions.
Identifiants
pubmed: 35325259
doi: 10.1007/s00125-022-05675-9
pii: 10.1007/s00125-022-05675-9
pmc: PMC9076751
doi:
Substances chimiques
Blood Glucose
0
Insulin
0
Urocortins
0
Somatostatin
51110-01-1
Glucagon
9007-92-5
Glucose
IY9XDZ35W2
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1018-1031Informations de copyright
© 2022. The Author(s).
Références
J Clin Invest. 1995 Jun;95(6):2799-805
pubmed: 7769119
BMC Genomics. 2014 Jul 22;15:620
pubmed: 25051960
Cell Metab. 2015 Feb 3;21(2):323-334
pubmed: 25651184
J Clin Invest. 1998 Aug 15;102(4):764-74
pubmed: 9710445
Diabetes. 2019 May;68(5):1062-1072
pubmed: 30733330
Proc Natl Acad Sci U S A. 2001 Jun 19;98(13):7570-5
pubmed: 11416224
Mol Metab. 2016 May 03;5(7):449-458
pubmed: 27408771
Endocrinology. 1987 Jul;121(1):323-31
pubmed: 3297643
Front Endocrinol (Lausanne). 2013 Jan 07;3:180
pubmed: 23316185
Regul Pept. 2012 Nov 10;179(1-3):91-100
pubmed: 22989472
Am J Physiol Regul Integr Comp Physiol. 2001 Nov;281(5):R1401-10
pubmed: 11641109
Ups J Med Sci. 2016 May;121(2):81-95
pubmed: 27124642
Cell Metab. 2016 Oct 11;24(4):593-607
pubmed: 27667667
Endocrinology. 1980 Feb;106(2):547-52
pubmed: 6986256
Peptides. 2004 Oct;25(10):1733-44
pubmed: 15476940
Diabetologia. 2013 Jun;56(6):1413-6
pubmed: 23519462
J Gen Physiol. 1997 Sep;110(3):217-28
pubmed: 9276750
Proc Natl Acad Sci U S A. 2007 Mar 6;104(10):4206-11
pubmed: 17360501
Endocrinology. 2003 Jul;144(7):3216-24
pubmed: 12810578
Br J Pharmacol. 2004 Oct;143(4):508-14
pubmed: 15381637
Acta Physiol (Oxf). 2020 Jul;229(3):e13464
pubmed: 32145704
Pharm Res. 2012 Apr;29(4):1078-86
pubmed: 22179928
Exp Ther Med. 2011 Mar;2(2):333-335
pubmed: 22977506
Br J Clin Pharmacol. 2009 Dec;68(6):804-10
pubmed: 20002075
Nat Med. 2015 Jul;21(7):769-76
pubmed: 26076035
PLoS One. 2012;7(12):e52181
pubmed: 23251699
J Pharmacol Exp Ther. 2002 May;301(2):611-7
pubmed: 11961064